bpc-157 human clinical trials dosing dosage BPC-157 (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or BPC 157 Australia Guide |
Description
Work to minimize environmental and lifestyle contributors
Your provider will determine the optimal schedule based on biomarker trends and symptom improvement over 812 weeks
Weakness Muscle spasms can sometimes cause temporary muscle weakness due to the intense pain and tightening of the affected muscles
Ergonomic optimization
Before adjusting your protocol, check your storage conditions and verify the medication has not passed its BUD or expiration date
Regular sterile water lacks this protection and should only be used for single-dose preparations
